

REF			SYSTEM
09744754190	09744754500	100	<b>cobas e 402</b> <b>cobas e 801</b>

## English

### System information

Short name	ACN (application code number)	Application
TNTHSX	10239	18 minutes
TNTHSSTX	10240	9 minutes (STAT = Short Turn Around Time)

### Intended use

Immunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma. This assay can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction (AMI), and as an aid for early discharge and outpatient management for patients suspected of acute coronary syndrome (ACS). The test is further indicated for the risk stratification of patients presenting with acute coronary syndrome and for cardiac risk in patients with chronic renal failure. The test may also be useful for the selection of more intensive therapy and intervention in patients with elevated levels of cardiac troponin T (cTnT).

In addition, this test can be used in the context of non-cardiac surgeries to predict pre-operatively the perioperative risk of major adverse cardiac events and in diagnosis of perioperative myocardial infarction (PMI) and myocardial injuries after non-cardiac surgeries (MINS).

The cTnT-hs values may also be used, in conjunction with clinical and diagnostics findings, to aid in stratifying the long-term risk of cardiovascular death, myocardial infarction, coronary revascularization, heart failure or ischemic stroke, and all-cause mortality in asymptomatic individuals.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.

### Summary

Troponin T (TnT) is a component of the contractile apparatus of the striated musculature. Although the function of TnT is the same in all striated muscles, TnT originating exclusively from the myocardium (cardiac TnT, molecular weight 39.7 kDa) clearly differs from skeletal muscle TnT. As a result of its high tissue-specificity, cTnT is a cardio-specific, highly sensitive marker for myocardial damage. Cardiac troponin T increases rapidly after acute myocardial infarction (AMI) and may persist up to 2 weeks thereafter.<sup>1,2,3</sup> Early detectability of the cTn increase in blood depends on the analytical sensitivity of the specific troponin test used; cardiac troponin T-high sensitive (cTnT-hs) helped to reduce the observational time from 6 to 3 hours when compared to conventional cardiac troponin (cTn) tests as suggested by several studies<sup>4,5,6</sup> and recommended by the 2011 ESC and the 2014 NICE guidelines on non-ST elevation myocardial infarction (NSTEMI).<sup>7,8</sup> The 2015 and 2020 ESC guidelines on NSTEMI propose to further shorten the observation time to 0 h/1 h. This accelerated approach to rule-in or rule-out AMI within 0 h/1 h has to be used with high-sensitive cardiac Troponin (hs-cTn) tests in conjunction with information from medical history and findings from clinical examination, ECG, additional laboratory and imaging information.<sup>9,10,11,12</sup> The specific algorithm values for cTnT-hs were recommended in these guidelines and have been validated in 3 studies, APACE, APACE-2015 and 2020 TRAPID-AMI as well as in additional prospective trials.<sup>13,14,15,16,17,18,19,20</sup> Alternative approaches using cTnT-hs to rule-in or rule-out AMI within 2 hours with or without risk scores have been also developed.<sup>9,21,22,23,24,25,26</sup>

In contrast to ST elevation myocardial infarction (STEMI), the diagnosis of NSTEMI heavily relies on measured cTn results. According to the new Universal Definition of myocardial infarction (MI), is diagnosed when blood levels of cTn are above the 99<sup>th</sup> percentile of the reference limit (of a healthy population) together with evidence of myocardial ischemia (symptoms, electrocardiogram (ECG) changes or imaging results). The definition requires a cTn assay with an imprecision (coefficient of variation) at the 99<sup>th</sup> percentile less than or equal to 10 %.<sup>27</sup>

cTnT is an independent prognostic marker which can predict the near-, mid- and even long-term outcome of patients with ACS.<sup>28,29,30,31</sup>

In addition, 4 multicenter trials involving more than 7000 patients have shown that cTnT is also useful to identify patients that benefit from anti-thrombotic therapy (GPIIb/IIIa inhibitors, low molecular weight heparin).<sup>32,33,34,35,36</sup>

The results of a sub-study of the PLATO trial, involving 9946 patients hospitalized for NSTEMI-ACS, also support the use of cTnT-hs testing to identify which NSTEMI-ACS patients will benefit most from an aggressive anti-platelet treatment strategy.<sup>37</sup>

Cardiac troponin has been reconfirmed as the preferred marker of myocardial injury in the new guidelines for the diagnosis and treatment of non-ST elevation myocardial infarction (NSTEMI).<sup>9,38</sup>

Cardiac troponins are released during the process of myocyte necrosis. While they are cardiac specific, they are not specific of MI only. To distinguish between acute and chronic cTn elevations, the Universal Definition of AMI requires the need for serial sampling to observe a rise and/or fall of cTn with at least one value above the 99<sup>th</sup> percentile upper reference limit. Absolute changes in cTn appear to have a higher diagnostic accuracy for AMI compared to relative changes.<sup>27,39</sup> Results interpretation have to be analyzed integrating the clinical assessment, including ischemic symptoms and electrocardiographic changes.

The Universal Definition of AMI recognizes that the improved analytical sensitivity of cTn assays used over the last years have allowed for detection of myocardial injury associated with other etiologies.<sup>27</sup> Chronic elevations of cTn can be detected in clinically stable patients such as patients with ischemic or non-ischemic heart failure,<sup>40,41,42</sup> in patients with different forms of cardiomyopathy,<sup>43</sup> renal failure,<sup>44,45,46,47,48,49</sup> sepsis<sup>50</sup> and diabetes.<sup>51,52</sup>

Elevated levels of cTnT correlate with the severity of coronary artery disease and to poor outcome independent of natriuretic peptide (NT-proBNP or BNP) levels.<sup>53,54</sup>

The 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the fourth definition of Acute Myocardial Infarction recognize the role of cTn in risk stratification and decision-making in patients with Acute Heart Failure (AHF). These guidelines recommend in addition to B-type natriuretic peptides the measurement of cTn upon presentation, in all patients with acute dyspnea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnea or to exclude myocardial injury or type 1 AMI.<sup>55,27</sup>

Cardiac troponin T values are an independent predictor of cardiovascular events including occurrence and recurrence of atrial fibrillation (AF).<sup>56</sup>

Recently, cTnT-hs has also been included into the "ABC-bleeding risk score" taking into account age, biomarkers (GDF-15, cTnT-hs, and hemoglobin) and history of bleeding, and into the "ABC-stroke risk score" taking into account age, NT-proBNP, cTnT-hs, and prior stroke/transient ischemic attack. The ABC-bleeding risk score was shown to significantly improve the prediction of bleeding events of AF patients.<sup>57</sup> The ABC-bleeding risk score could therefore be a valuable decision support tool regarding indications for and selection of treatment with oral anticoagulants in patients with AF.<sup>58</sup> Results of the ENGAGE AF-TIMI 48 trial evaluating the ABC-stroke and the ABC-bleeding risk scores confirmed that these scores may help to identify AF patients most likely to benefit from treatment with non-vitamin K antagonist oral anticoagulants (NOACs).<sup>58</sup>

Myocardial cell injury leading to elevated cTnT concentrations in the blood can also occur in other clinical conditions such as myocarditis,<sup>59</sup> heart contusion,<sup>60</sup> pulmonary embolism,<sup>61</sup> kidney disease<sup>62</sup> and drug-induced cardiotoxicity.<sup>63</sup> In patients with COVID-19, cTnT levels above the 99<sup>th</sup> percentile upper reference limit were frequently reported on admission and during the course of the disease.<sup>64,65,66,67</sup> Elevated cTnT levels indicate myocardial injury and may predict the necessity of intensive care unit admission, invasive ventilation and the occurrence of mortality.<sup>65,66,67,68,69</sup>

Several studies in the general population have shown that cTnT-hs elevations below the 99<sup>th</sup> percentile upper reference limit (URL) can have prognostic value for increased risk of cardiovascular disease. This association was strongest for fatal CVD and applies to both Coronary Heart Disease (CHD) and stroke, and persisted after adjustment for conventional risk factors.<sup>70,71,72,73,74,75,76</sup>

Other diagnostic tests such as NT-proBNP or GDF-15 can complement the diagnostic and prognostic information of cTnT-hs in patients with heart

# Elecsys Troponin T hs

failure and renal dysfunction.<sup>77,78</sup> The results of the FRISC-II study suggest that in patients with non-ST elevation ACS, prioritisation for early invasive procedures might be facilitated by use of biomarkers such as cTnT-hs and GDF-15.<sup>78</sup>

Measurements of cTnT-hs before non-cardiac surgery can be used to predict the peri-operative occurrence of major adverse cardiac events (MACE), such as cardiovascular death, MI<sup>79</sup> and for the peri-operative diagnosis of myocardial injury after non-cardiac surgery (MINS)<sup>80</sup> and for the peri-operative myocardial injury/infarction (PMI).<sup>81</sup> Cardiac troponin changes during surgery and cTn peak elevations within the first 3 days after surgery can be used to predict MACE, and to diagnose MINS, PMI or MI.<sup>27,82,83,84</sup>

The Elecsys Troponin T hs assay employs two monoclonal antibodies specifically directed against human cTnT.<sup>85,86</sup> The antibodies recognize two epitopes (amino acid position 125-131 and 136-147) located in the central part of the cTnT protein, which consists of 288 amino acids.

The Troponin T hs calibrators (Troponin T hs CalSet) contain recombinant human cardiac troponin T (rec. hcTnT). The rec. hcTnT is isolated from cell culture of *E. coli* BL21 containing a pET vector with human cTnT isoform 3 gene. After fermentation, the cells are disrupted by sonication and rec. hcTnT is purified by ion exchange chromatography. Purified rec. hcTnT is further characterized by SDS PAGE, Western blotting, immunological activity, and protein content.<sup>87</sup>

The International Federation of Clinical Chemistry (IFCC) has assigned the term "High-sensitivity (hs)" to cTn assays that have a CV of  $\leq 10\%$  at the 99<sup>th</sup> percentile value and  $\geq 50\%$  of the detectable values above the Limit of Detection in a healthy reference population of both genders.<sup>88</sup> Compliance to these 2 criteria have been externally confirmed.<sup>89</sup>

## Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: Antigen in the sample (30  $\mu$ L), a biotinylated monoclonal cardiac troponin T-specific antibody, and a monoclonal cardiac troponin T-specific antibody labeled with a ruthenium complex<sup>a)</sup> react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.

Total duration of assay: 9 minutes.

- During a 9-minute incubation, antigen in the sample (30  $\mu$ L), a biotinylated monoclonal cardiac troponin T-specific antibody, a monoclonal cardiac troponin T-specific antibody labeled with a ruthenium complex and streptavidin-coated microparticles react to form a sandwich complex, which is bound to the solid phase.

For both assay applications:

- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the **cobas** link.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<sub>3</sub><sup>2+</sup>)

## Reagents - working solutions

The **cobas e** pack is labeled as TNTHSX.

- M Streptavidin-coated microparticles, 1 bottle, 6.4 mL:  
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-cardiac troponin T-Ab-biotin, 1 bottle, 7.4 mL:  
Biotinylated monoclonal anti-cardiac troponin T-antibody (mouse) 2.5 mg/L; phosphate buffer 100 mmol/L, pH 6.0; preservative; inhibitors.
- R2 Anti-cardiac troponin T-Ab-Ru(bpy)<sub>3</sub><sup>2+</sup>, 1 bottle, 7.4 mL:  
Monoclonal anti-cardiac troponin T-antibody (mouse) labeled with ruthenium complex 2.5 mg/L; phosphate buffer 100 mmol/L, pH 6.0; preservative.

## Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



Warning

H317 May cause an allergic skin reaction.

## Prevention:

P261 Avoid breathing mist or vapours.

P272 Contaminated work clothing should not be allowed out of the workplace.

P280 Wear protective gloves.

## Response:

P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

## Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

## Reagent handling

The Elecsys Troponin T hs assay can be used for both the 9-minute application and the 18-minute application.

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is available via the **cobas** link.

## Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the **cobas e** pack **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
on the analyzers	16 weeks

## Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

K<sub>2</sub>-EDTA, K<sub>3</sub>-EDTA, Li-heparin and Na-heparin plasma.

Plasma tubes containing separating gel can be used.

Plasma (EDTA, heparin) and serum samples should not be used interchangeably.

# Elecsys Troponin T hs

Criterion: Slope 0.90-1.10 + coefficient of correlation  $\geq 0.95$ .

Stable for 24 hours at 2-8 °C, 12 months at -20 °C ( $\pm 5$  °C). Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Re-centrifuge K2/K3-EDTA plasma samples in a secondary tube for 5 minutes at 3000 x g or 30 seconds at 10000 x g prior to measurement.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

## Materials provided

See "Reagents – working solutions" section for reagents.

## Materials required (but not provided)

- [REF] 09315373190, CalSet Troponin T hs, for 4 x 1.0 mL
- [REF] 05095107190, PreciControl Troponin, for 4 x 2.0 mL
- [REF] 07299010190, Diluent MultiAssay, 36 mL sample diluent
- General laboratory equipment
- **cobas e** analyzer

Additional materials for **cobas e** 402 and **cobas e** 801 analyzers:

- [REF] 06908799190, ProCell II M, 2 x 2 L system solution
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 07485409001, Reservoir Cup, 8 cups to supply ProCell II M and CleanCell M
- [REF] 06908853190, PreClean II M, 2 x 2 L wash solution
- [REF] 05694302001, Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners
- [REF] 07485425001, Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- [REF] 07485433001, PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use.

Place the cooled (stored at 2-8 °C) **cobas e** pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the **cobas e** pack.

## Calibration

Traceability: The Elecsys Troponin T hs assay ([REF] 08469873190 / 09315357190) has been standardized against the Elecsys Troponin T STAT assay ([REF] 04660307190). This in turn was originally standardized against the Enzymun-Test Troponin T (CARDIAC T) method.

The predefined master curve is adapted to the analyzer using the relevant CalSet.

**Calibration frequency:** Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the **cobas e** pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 28 days when using the same **cobas e** pack on the analyzer
- as required: e.g. quality control findings outside the defined limits

## Quality control

Use PreciControl Troponin or other suitable controls for routine quality control procedures.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per **cobas e** pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

## Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in pg/mL, ng/L, ng/mL or µg/L).

## Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

### Endogenous substances

Compound	Concentration tested
Bilirubin	$\leq 428$ µmol/L or $\leq 25$ mg/dL
Hemoglobin	$\leq 0.062$ mmol/L or $\leq 100$ mg/dL
Intralipid	$\leq 1500$ mg/dL
Biotin	$\leq 4.92$ µmol/L or $\leq 1200$ ng/mL
Rheumatoid factors	$\leq 1200$ IU/mL
Albumin	$\leq 7$ g/dL

Criterion: Recovery of  $\pm 2.8$  pg/mL of initial value  $< 14$  pg/mL,  $\pm 20$  % of initial value 14-100 pg/mL and  $\pm 10$  % of initial value  $> 100$  pg/mL.

Falsely depressed results are obtained when using samples with hemoglobin concentrations  $> 0.1$  g/dL.

There is no high-dose hook effect at troponin T concentrations up to 100000 ng/L (pg/mL).

### Pharmaceutical substances

In vitro tests were performed on 17 commonly used pharmaceuticals. No interference with the assay was found.

In addition, the following special cardiac drugs were tested. No interference with the assay was found.

### Special cardiac drugs

Drug	Concentration tested mg/L
Carvedilol	37.5
Clopidogrel	75
Digoxin	0.25
Epinephrine	0.5
Insulin aspart	1.6
Lidocaine	80
Lisinopril	10
Methylprednisolone (Urbason)	7.5
Metoprolol	150
Nifedipine	30
Phenprocoumon	3

# Elecsys Troponin T hs

Drug	Concentration tested mg/L
Propafenone	300
Retepase	33.3
Simvastatin	30
Spironolactone	75
Tolbutamide (Glibenclamide)	1500
Torasemide	15
Verapamil	240
Valsartan	206
Sacubitril	194
Dabigatran	300
Rivaroxaban	40

Drug interferences are measured based on recommendations given in CLSI guidelines EP07 and EP37 and other published literature. Effects of concentrations exceeding these recommendations have not been characterized.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

## Limits and ranges

### Measuring range

3-10000 ng/L or pg/mL (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Detection are reported as < 3 ng/L or pg/mL. Values above the measuring range are reported as > 10000 ng/L or pg/mL (or up to 100000 ng/L or pg/mL for 10-fold diluted samples).

### Lower limits of measurement

*Limit of Blank, Limit of Detection and Limit of Quantitation*

Limit of Blank = 2.5 ng/L (pg/mL)

Limit of Detection = 3 ng/L (pg/mL)

Limit of Quantitation = 13 ng/L (pg/mL)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from  $n \geq 60$  measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation (functional sensitivity) is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of  $\leq 10$  %.

An internal study was performed based on guidance from the CLSI protocol EP17-A2. Limit of Blank, Limit of Detection and Limit of Quantitation were determined to be the following-see table below. In addition for analyte concentration that can be reproducibly measured with an intermediate precision CV of  $\leq 20$  % the following results were obtained:

	18-min application	9-min application
Limit of Blank (ng/L = pg/mL)	2.21	1.91
Limit of Detection (ng/L = pg/mL)	2.97	2.72

Limit of Quantitation 10 % intermediate CV (ng/L = pg/mL)	5.40	3.22
20 % intermediate CV (ng/L = pg/mL)	2.30	1.00

### Dilution

Samples with cTnT concentrations above the measuring range can be diluted with Diluent MultiAssay. The recommended dilution is 1:10 (either automatically by the analyzers or manually). The concentration of the diluted sample must be  $\geq 1000$  ng/L (pg/mL).

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzers, the software automatically takes the dilution into account when calculating the sample concentration.

### Expected values

In studies performed with the Elecsys Troponin T hs assay involving 533 healthy volunteers (age range: 20-71 years), the upper reference limit (URL) (99<sup>th</sup> percentile) for troponin T was determined at 14 ng/L (pg/mL), 95 % confidence interval 12.7-24.9 ng/L (pg/mL).<sup>90</sup> This study also defines the 99<sup>th</sup> percentile URL at 9.0 ng/L (pg/mL) for females ( $n = 265$ ) and 16.8 ng/L (pg/mL) for males ( $n = 268$ ) using a non-parametric approach. Of these 533 volunteers, 306 (57.4 %) had a cTn value above 3 ng/L (pg/mL).<sup>90</sup> Several publications report that using cTnT-hs, sex-specific cutoffs do not add clinical value compared to one overall cutoff.<sup>91,92,93,94,95,96,97</sup>

Based on the WHO criteria for the definition of AMI<sup>98</sup> from the 1970's, the cutoff (clinical discriminator) value for troponin T is 0.1  $\mu$ g/L (ng/mL) or 100 ng/L (pg/mL) as determined from ROC analysis in results with an earlier test generation of the Elecsys Troponin T assay.<sup>99,100</sup>

The WHO definition of AMI has been recently updated and takes into consideration the ESC/ACCF/AHA/WHF definition recommending the detection of a rise and/or fall of cardiac troponin in the clinical setting of myocardial ischemia using the 99<sup>th</sup> percentile troponin cutoff value.<sup>101</sup>

Due to the release kinetics of cTnT, an initially test result < 99<sup>th</sup> percentile within the first hour of the onset of symptoms does not rule out MI in all patients. Therefore lower cutoffs have been proposed for immediate rule-out and also specific delta changes for 0 h/1 h algorithms.<sup>9</sup> Additional testing at appropriate time intervals is indicated if the first measurements are not conclusive and the clinical condition is still suggestive of ACS.<sup>9</sup> The cTn values should always be used in conjunction with full clinical assessment (including chest pain characteristics and ECG).

**ESC 0 h/1 h rule-in and rule-out diagnostic algorithm using cTnT-hs assay in patients presenting with suspected NSTEMI to the emergency department (ED).<sup>9</sup>**

cTnT-hs concentration (ng/L or pg/mL)	cTnT-hs values in patients suspected of NSTEMI			
	0 h < 5 <sup>*</sup>	0 h < 12 and $\Delta$ 0-1 h < 3	other	0 h $\geq$ 52 or $\Delta$ 0-1 h $\geq$ 5
Orientation for the diagnosis of AMI	Rule-out	Rule-out	Observe	Rule-in

0 h and 1 h refer to the time since the first blood test.

<sup>\*</sup> Only applicable if chest pain inset > 3 h.

Besides cTn, clinical evidence of myocardial ischemia is requested for the diagnosis of AMI and caution is advised when dealing with patient subsets such as elderly, critical ill individuals with sepsis or end-stage renal disease, those who present with atypical symptoms and those who present very early after the onset of symptoms.

As recommended in the ESC guidelines, it is important to obtain a careful history and a precise description of the symptoms. A physical examination with particular attention to the possible presence of cardiac contusion, acute and chronic heart failure, aortic dissection, aortic valve disease, hypertrophic cardiomyopathy, tachy- or bradyarrhythmias, apical ballooning syndrome, rhabdomyolysis with cardiac injury, pulmonary embolism, severe pulmonary hypertension, acute neurological disease, infiltrative diseases, drug toxicity, respiratory failure, sepsis, burns and other conditions is required.<sup>9,27</sup>

An ECG is recorded for allowing differentiation of patients with or without ST-segment changes.

# Elecsys Troponin T hs



Laboratory assessment of patients with suspicion of ACS should include markers of myocardial damage, preferably cTn.<sup>9</sup> If concentrations of cTn or cardiac enzymes rise, irreversible myocyte cell damage will have occurred and these patients must be regarded as having had myocardial damage.

*Factors associated with elevated values*<sup>27,59,102,103,104,105</sup>

Published clinical studies have shown elevations of cTn in patients with myocardial injury, as seen in unstable angina pectoris, cardiac contusions, and heart transplants. Elevations have also been seen in patients with rhabdomyolysis and polymyositis.

The ESC and AHA/ACC guidelines and the Universal Definition of MI recommend serial sampling with a rise or fall in cTn to distinguish between acute and chronic cTn elevations. Results should be interpreted in conjunction with clinical presentation including medical history, signs and symptoms, ECG data and biomarker concentrations.<sup>9,27,38</sup>

## For peri-operative myocardial injury/infarction after non-cardiac surgeries (MINS/PMI)

According to Devereaux JP et al.<sup>106,107</sup> the diagnostic criteria of MINS are peak operative cTnT-hs values  $\geq 20$  ng/L with an absolute delta change between two measurements of  $\geq 5$  ng/L (pg/mL), or absolute values  $\geq 65$  ng/L (pg/mL) judged as resulting from myocardial ischemia (i.e. no evidence of a non-ischemic etiology) within 30 days after non-cardiac surgery and without the requirement of an ischemic feature (e.g. ischemic symptom, ischemic electrocardiography findings).<sup>106</sup>

The pathophysiology of MINS in surgical patients differs from that of MI in medical (non-surgical) patients.<sup>108</sup> According to Puelacher C et al.<sup>81</sup> diagnostic criteria for PMI are defined as an absolute increase in TnT-hs of  $\geq 14$  ng/L (pg/mL) between pre-operative and peak post-operative values (or between 2 post-operative values if the pre-operative value was missing) within 7 days of surgery.<sup>81</sup> Clinical guidelines recommend to consider peri-operative cTn testing before and 48-72 hours after major non-cardiac surgery of patients at high-risk for cardiovascular disease such as  $> 45$  years old patients with a known history of cardiovascular disease and/or patients  $\geq 65$  years.<sup>82,83</sup> See result section for more details.

## Expected values for asymptomatic individuals

According to the analysis of major publications, the following concentration range may be used to aid stratifying the long-term risk of cardiovascular disease in asymptomatic individuals.<sup>72,74,109,110,111</sup>

## Proposed ranges/cutoff values for cardiovascular risk estimation in asymptomatic individuals

cTnT-hs range (ng/L or pg/mL)	< 5	5 - < 10	$\geq 10$
Risk category	Low	Intermediate	High

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

## Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

## Precision

Precision was determined using Elecsys reagents, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

cobas e 402 and cobas e 801 analyzers (18-minutes application)					
Sample	Mean ng/L (pg/mL)	Repeatability		Intermediate precision	
		SD ng/L (pg/mL)	CV %	SD ng/L (pg/mL)	CV %
Human serum 1	9.73	0.449	4.6	0.649	6.7
Human serum 2	12.5	0.522	4.2	0.631	5.0
Human serum 3	21.4	0.506	2.4	0.781	3.6
Human serum 4	166	3.62	2.2	5.65	3.4

cobas e 402 and cobas e 801 analyzers (18-minutes application)					
Sample	Mean ng/L (pg/mL)	Repeatability		Intermediate precision	
		SD ng/L (pg/mL)	CV %	SD ng/L (pg/mL)	CV %
Human serum 5	5557	139	2.5	224	4.0
Human serum 6	9984	209	2.1	459	4.6
PreciControl TN1	28.3	0.575	2.0	0.977	3.5
PreciControl TN2	2136	24.9	1.2	61.2	2.9

cobas e 402 and cobas e 801 analyzer (9-minutes application)					
Sample	Mean ng/L (pg/mL)	Repeatability		Intermediate precision	
		SD ng/L (pg/mL)	CV %	SD ng/L (pg/mL)	CV %
Human serum 1	9.87	0.266	2.7	0.537	5.4
Human serum 2	12.2	0.311	2.5	0.528	4.3
Human serum 3	21.6	0.351	1.6	0.777	3.6
Human serum 4	156	3.24	2.1	6.01	3.9
Human serum 5	4740	38.8	0.8	144	3.0
Human serum 6	9172	79.0	0.9	314	3.4
PreciControl TN1	26.5	0.399	1.5	0.864	3.3
PreciControl TN2	1964	24.1	1.2	55.6	2.8

## Method comparison

a) A comparison of the Elecsys Troponin T hs assay, [REF] 08469873190 / 09315357190 (cobas e 801 analyzer; 18-min. application; y) with the Elecsys Troponin T hs assay, [REF] 07028075190 (cobas e 801 analyzer; 18-min. application; x), using clinical samples gave the following correlations (ng/L or pg/mL):

Number of samples measured: 155

Passing/Bablok<sup>112</sup> Linear regression

$$y = 0.999x + 1.04 \quad y = 0.990x + 6.27$$

$$\tau = 0.951 \quad r = 1.00$$

The sample concentrations were between 3 and 9200 ng/L (pg/mL).

b) A comparison of the Elecsys Troponin T hs assay, [REF] 08469873190 / 09315357190 (cobas e 801 analyzer; 9-min. application; y) with the Elecsys Troponin T hs assay, [REF] 08469873190 / 09315357190 (cobas e 801 analyzer; 18-min. application; x), using clinical samples gave the following correlations (ng/L or pg/mL):

Number of samples measured: 158

Passing/Bablok<sup>112</sup> Linear regression

$$y = 1.00x + 0.132 \quad y = 1.02x - 0.235$$

$$\tau = 0.966 \quad r = 1.00$$

The sample concentrations were between 3 and 9700 ng/L (pg/mL).

c) A comparison of the Elecsys Troponin T hs assay, [REF] 08469873190 / 09315357190 (cobas e 402 analyzer; 18-min. application; y) with the Elecsys Troponin T hs assay, [REF] 08469873190 / 09315357190 (cobas e 801 analyzer; 18-min. application; x) gave the following correlations (ng/L or pg/mL):

Number of samples measured: 158

Passing/Bablok<sup>112</sup> Linear regression

$$y = 1.04x - 0.945 \quad y = 1.01x + 8.37$$

$$\tau = 0.966 \quad r = 0.999$$

# Elecsys Troponin T hs



The sample concentrations were between 4.67 and 9682 ng/L (pg/mL).

### Analytical specificity

The Elecsys Troponin T hs assay does not show any significant cross-reaction with the following substances (tested with TnT concentrations of approximately 18 ng/L (pg/mL); concentration of cross-reacting substances 500 ng/mL):

- h-skeletal muscle troponin T 0.066 %, h-cardiac troponin I 0.017 %, h-skeletal muscle troponin I 0.006 %, human troponin C 0.0003 %.

### Diagnostic sensitivity and specificity

One clinical center in Germany, one center in India, one center in Switzerland, and two centers in the US participated in prospective studies in patients presenting with chest pain in the emergency department. 507 patients were ruled in for calculation of sensitivity and specificity as selected by the following criteria: Chest pain for > 20 minutes, assessment by 12-lead ECG, age > 20 years, no pregnancy, no previous MI within 3 weeks before admission and a minimum of two blood draws. The patients were diagnosed for acute MI by application of:

1. WHO criteria<sup>98</sup> including criteria: Chest pain for > 20 minutes, assessment by 12-lead ECG, age > 20 years, no pregnancy, no previous MI within 3 weeks before admission and a minimum of two blood draws. The patients were diagnosed for acute MI by application of:
2. Criteria defined by the Joint ESC/ACCF/AHA/WHF task force.<sup>113</sup>

### Sensitivity and specificity calculated with AMI defined according to the ESC/ACCF/AHA/WHF guidelines

Patients with AMI were defined by routine cTn values above the 99<sup>th</sup> percentile/10 % CV criteria, and presence of chest pain or ECG changes. Sensitivity and specificity at peak cTnT-hs values were calculated at the 99<sup>th</sup> percentile of 14 ng/L (pg/mL).

Sensitivity %	N	95 % confidence interval (%)	Specificity %	N	95 % confidence interval (%)
100	112/112	97-100	75	297/395	71-79

Sensitivity and specificity of the Elecsys Troponin T hs assay were calculated at different cTnT-hs levels.

cTnT-hs pg/mL	Sensitivity %	LCI <sup>b)</sup> %	UCI <sup>c)</sup> %	Specificity %	LCI %	UCI %
30	98	93.7	99.5	93	90.0	95.1
50	95	88.8	97.5	98	96.1	99.0
70	84	76.0	89.6	99	98.2	99.9
100	75	66.2	82.1	99	98.2	99.9

b) LCI = lower confidence interval

c) UCI = upper confidence interval

The sensitivity and specificity at the 99<sup>th</sup> percentile (Elecsys Troponin T hs assay)/10 % CV (Elecsys Troponin T assay, 4<sup>th</sup> gen.; 0.03 ng/mL) criteria were in addition calculated for different time intervals from admission to the hospital:

Time from admission (hours)	Test generation cTnT	Sensitivity %	N	95 % CI <sup>d)</sup> (%)	Specificity %	N	95 % confidence interval (%)
0	4th gen.	71	40/56	58-83	99	142/143	96-100
	Troponin T hs	93	52/56	83-98	76	109/143	68-83
0-3	4th gen.	81	75/93	71-88	99	356/359	98-100
	Troponin T hs	98	91/93	93-100	79	282/359	74-83
3-6	4th gen.	83	53/64	71-91	100	300/301	98-100
	Troponin T hs	100	64/64	94-100	77	232/301	72-82
6-9	4th gen.	86	42/49	73-94	99	201/203	97-100
	Troponin T hs	98	48/49	89-100	76	155/203	70-82
9-12	4th gen.	83	15/18	59-96	100	43/43	92-100
	Troponin T hs	94	17/18	73-100	72	31/43	56-85
> 12	4th gen.	83	25/30	65-94	98	56/57	91-100
	Troponin T hs	100	30/30	88-100	60	34/57	46-72

d) confidence interval

### Results using the cTnT-hs 0 h/1 h algorithm recommended by the ESC Guidelines for ACS patients presenting without persistent ST-elevation

Negative predictive value (NPV) values from prospective trials using cTnT-hs 0 h/1 h diagnostic algorithm recommended by the 2020 Guidelines for patients presenting to the ED with suspected NSTEMI are depicted in the table below for the assignment of patients to the rule-out zone discharged from the ED.<sup>9,13,14,15,16,17,18,19</sup>

Publications and trials	Using cTnT-hs values for patient assignment to the rule-out zone: 0 h < 12 ng/L and Δ 1 h < 3 ng/L	
	Negative predictive value (NPV)	All-cause mortality or MACE in Rule out
APACE <sup>13</sup>	100 %	30 days all-cause mortality: 0.2 % 2 years all-cause mortality: 1.9 %
APACE <sup>14</sup>	99.9 % (95 % CI: 99.3-100 %)	30 days all-cause mortality: 0 % 2 years all-cause mortality: 1.1 %
TRAPID-AMI <sup>15</sup>	99.1 % (95 % CI: 98.2-99.7 %)	30 days all-cause mortality: 0.1 % 2 years all-cause mortality: 0.7 %
Mokhtari et al. <sup>16</sup>	NPV for 30 days MACE: 97.8 % (95 % CI: 98.6-99.9 %) using the extended algorithm (+non-ischaemic ECG + no high-risk history)	30 days MACE: 2.2 % 30 days MACE with the extended algorithm: 0.5 % (0 % when excluding unstable angina)
Using cTnT-hs values for patient assignment to the rule-out zone: 0 h < 5 ng/L or 0 h < 12 ng/L and Δ 1 h < 3 ng/L		
APACE <sup>19</sup>	100 %	30 days and 1-year all-cause mortality: 0.2 %
RAPID-TnT <sup>18</sup>	99.6 % (95 % CI: 99.0-99.9 %) for 30 days death or MI	30 days all-cause death and MI: 0.4 %
Shiozaki et al. <sup>17</sup>	100 % (95 % CI: 96.8-100 %)	30 days all-cause mortality: 0 %

### Results from major trials using cTnT-hs to help for the diagnosis and predict MINS and PMI after non-cardiac surgeries

Data from the global, multicentric VISION study (Vascular Events in Noncardiac Surgery patients Cohort Evaluation)<sup>106</sup>

The VISION study was a global, prospective, multicentric cohort study enrolling 21848 patients aged ≥ 45 years undergoing inpatient non-cardiac surgery. Association between peri-operative (pre-, post- and absolute peri-operative changes) cTnT-hs levels and 30 days mortality as well as potential diagnostic criteria for MINS were determined. Descriptive statistics for specific peri-operative levels are depicted in the following tables.

### Perioperative cTnT-hs levels (1 day before surgery in the majority of patients) with associated hazard ratios (HRs) for various adverse cardiovascular outcomes 30 days post-surgery.

cTnT-hs (ng/L or pg/mL)	Unadjusted HR (95 % CI)				N (%)
	MINS / vascular death	Death	MI	MI / death	
< 14	1 (reference population)				78.4
≥ 14 to < 28	5.97 (5.34, 6.67)	2.46 (1.53, 3.95)	2.70 (2.13, 3.43)	2.74 (2.20, 3.40)	14.5
≥ 28	7.93 (6.96, 9.04)	7.49 (4.94, 11.36)	5.09 (3.98, 6.53)	5.49 (4.40, 6.84)	7.2

Additionally, cTnT-hs levels were measured 6-12 h post-operatively as well as on day 1, 2 and 3 after surgery to determine peak post-operative cTnT-hs levels which have been analyzed for estimation of the 30 days post-surgery mortality. Detection of an elevated cTnT-hs level in the post-operative period was found to be the strongest predictor of 30 day mortality.<sup>106</sup>

# Elecsys Troponin T hs



cTnT-hs (ng/L or pg/mL)	Adjusted HR	95 % CI (%)	N (%)
≥ 1000	227.01	87.35 - 589.92	0.2
≥ 65 to < 1000	70.34	30.60 - 161.71	5.1
≥ 20 to < 65	23.63	10.32 - 54.09	18.6
≥ 14 to < 20	9.11	3.76 - 22.09	11.6
≥ 5 to < 14	3.73	1.58 - 8.82	40.1
< 5	1 (reference)		24.4

Furthermore, absolute changes in cTnT-hs between various combination of pre- and post-operative measurements 6-12 h, 1 day, 2 days or 3 days after surgery were analyzed with respect to mortality at 30 days.<sup>106</sup>

cTnT-hs (ng/L or pg/mL)	Adjusted HR (95 % CI)					
	Pre vs post operative cTnT-hs (n = 7857)	N (%)	Between any two post-operative cTnT-hs (n = 18023)	N (%)	Between any two cTnT-hs measurements (n = 19373)	N (%)
< 5	1 (reference)	65.1	1 (reference)	64.0	1 (reference)	61.7
≥ 5	4.53 (2.77-7.39)	34.9	5.24 (3.92-7.01)	36.0	4.69 (3.52- 6.25)	38.3

In the BASEL-PMI study (single-centric, 2028 consecutive patients), Puelacher C. *et al* defined PMI as an absolute increase in cTnT-hs of ≥ 14 ng/L between pre-operative and peak post-operative values (or between 2 post-operative values if the pre-operative value is missing) within 7 days of surgery. According to these criteria, patients with PMI had an adjusted HR of 2,7 for 30 days mortality compared to patients without PMI.<sup>81</sup>

### Results using cTnT-hs for long-term risk stratification in asymptomatic individuals

Results from the Atherosclerosis Risk community (ARIC) Study to predict coronary heart disease, fatal coronary heart disease and myocardial infarction, all-cause mortality, and heart failure hospitalization with increasing cTnT-hs values.<sup>72</sup>

Group	Adjusted HR (95% CI)				
	< 3 (ng/L or pg/mL)	3-5 (ng/L or pg/mL)	6-8 (ng/L or pg/mL)	9 -13 (ng/L or pg/mL)	≥ 14 (ng/L or pg/mL)
All CHD number of individuals	3258	2500	1971	1254	715
All CHD events	214	205	221	171	172
Model 1 <sup>e)</sup>	1 (reference)	1.06 (0.88-1.29)	1.33 (1.09-1.62)	1.50 (1.21-1.86)	2.97 (2.38-3.71)
Model 2 <sup>f)</sup>	1 (reference)	1.08 (0.89-1.31)	1.31 (1.07-1.59)	1.37 (1.10-1.71)	2.46 (1.96-3.08)
Model 3 <sup>g)</sup>	1 (reference)	1.07 (0.88-1.30)	1.29 (1.06-1.58)	1.34 (1.07-1.67)	2.29 (1.81-2.89)
Hard CHD (fatal CHD + MI)	3258	2500	1971	1254	715
Hard CHF, events	118	104	107	81	117
Model 1	1 (reference)	1.02 (0.78-1.33)	1.22 (0.93-1.60)	1.34 (0.99-1.82)	3.74 (2.81-4.99)
Model 2	1 (reference)	1.06 (0.81-1.39)	1.26 (0.96-1.67)	1.31 (0.96-1.78)	3.28 (2.44-4.42)
Model 3	1 (reference)	1.05 (0.80-1.38)	1.23 (0.93-1.62)	1.23 (0.90-1.68)	2.84 (2.09-3.86)
All-cause mortality	3258	2500	1971	1254	715
All-cause mortality events	217	246	248	234	265

Model	Adjusted HR	Adjusted HR (95% CI)			
		1	2	3	4
Model 1	1 (reference)	1.27 (1.05-1.52)	1.45 (1.20-1.76)	1.94 (1.59-2.37)	4.34 (3.55-5.29)
Model 2	1 (reference)	1.39 (1.15-1.67)	1.64 (1.35-1.98)	2.13 (1.74-2.60)	4.43 (3.61-5.44)
Model 3	1 (reference)	1.37 (1.14-1.65)	1.60 (1.32-1.94)	2.05 (1.68-2.51)	3.96 (3.21-4.88)
HF Hospitalization	3158	2413	1877	1188	640
HF Hospitalization events	105	124	147	130	159
Model 1	1 (reference)	1.45 (1.12-1.88)	2.21 (1.71-2.86)	3.07 (2.34-4.04)	8.61 (6.57-11.28)
Model 2	1 (reference)	1.51 (1.16-1.96)	2.24 (1.73-2.90)	2.84 (2.16-3.74)	7.00 (5.29-9.25)
Model 3	1 (reference)	1.46 (1.14-1.92)	2.17 (1.67-2.81)	2.68 (2.03-3.53)	5.95 (4.47-7.92)

e) Model 1: adjusted for age, sex, race.

f) Model 2: adjusted for model 1 + initial values for body mass index, smoking status and amount, diabetes mellitus, systolic blood pressure, antihypertensive medication use, high-density lipoprotein cholesterol, total cholesterol, lipid medication use, lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>), prevalent atrial fibrillation, coronary heart disease, and heart failure.

g) Model 3: adjusted the same as model 2 except incident atrial fibrillation, coronary heart disease, and heart failure were treated as time-dependent covariates.

Association of HR for stroke with increasing cTnT-hs values from the ARIC study.<sup>74</sup>

	cTnT-hs group (ng/L or pg/mL)	< 3	3-5	6-8	9-13	≥ 14	P trend
Stroke model							
No. for model 1		3492	2715	2214	1493	988	
No. for model 1 and 3		3317	2605	2105	1411	912	
Total stroke							
Rate/1000 person-year		2.79	3.18	3.20	4.93	7.71	
No. of strokes		109	106	95	103	94	
Model 1	1 (reference)	1.14 (0.97-1.50)	1.16 (0.87-1.54)	1.80 (1.34-2.40)	2.87 (2.11-3.91)	< 0.0001	
Model 2	1 (reference)	1.25 (0.94-1.65)	1.13 (0.84-1.53)	1.60 (1.17-2.18)	2.04 (1.45-2.87)	< 0.0001	
Model 3	1 (reference)	1.23 (0.93-1.63)	1.09 (0.81-1.48)	1.51 (1.11-2.06)	1.85 (1.31-2.61)	0.001	

See previous table for model definition.

### References

- Katus HA, Remppis A, Looser S, et al. Enzyme linked immunoassay of cardiac troponin T for the detection of acute myocardial infarction in patients. *Mol Cell Cardiol* 1989;21(12):1349-1353.
- Liebetrau C, Mollmann H, Nef H, et al. Release kinetics of biomarkers in patients undergoing transcatheter ablation of septal hypertrophy. *Clin Chem* 2012;58(6):1049-1054.
- Katus HA, Scheffold T, Remppis A, et al. Proteins of the troponin complex. *Laboratory Medicine* 1992;23(5):311-317.
- Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *NEJM* 2009;361(9):858-867.
- Giannitsis E, Becker M, Kurz K, et al. High sensitivity cardiac troponin T for early prediction of evolving non-ST segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin result on presentation. *Clin Chem* 2010;56(4):642-650.

- 6 Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity cardiac troponin T assay. *Clin Chem* 2010;56(2):254-261.
- 7 Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndrome in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndrome (ACS) in patient presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32(23):2999-3054.
- 8 NICE (2014) Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays). NICE diagnostics guidance DG15. Available at [www.nice.org.uk/dg15](http://www.nice.org.uk/dg15) [NICE guideline]
- 9 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2020. PMID 32860058.
- 10 Bandstein N, Ljung R, Johansson M, et al. Undetectable high sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. *J Am Coll Cardiol* 2014;63:2569-2578.
- 11 Body R, Burrows G, Carley S, et al. High-sensitivity cardiac troponin T concentrations below the limit of detection to exclude acute myocardial infarction: A prospective evaluation. *Clin Chem* 2015;61(7):983-989.
- 12 Rubini Gimenez M, Reichlin T, Zellweger C. Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. *Int J Cardiol* 2013;168(4):3896-3901.
- 13 Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. *Arch Intern Med* 2012;172(16):1211-1218.
- 14 Reichlin T, Twerenbold R, Wildi K, et al. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. *CMAJ* 2015;187(8):E243-252.
- 15 Mueller C, Giannitsis E, Christ M, et al. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac Troponin T. *Ann Emerg Med* 2016; 68(1):76-87.
- 16 Mokhtari A, Borna C, Gilje P, et al. A 1-h combination algorithm allows fast rule-out and rule-in of major adverse cardiac events *J Am Coll Cardiol* 2016;67(13):1531-1540.
- 17 Shiozaki M, Inoue K, Sua S, et al. Utility of the 0-hour/1-hour high-sensitivity cardiac troponin T algorithm in Asian patients with suspected non-ST elevation myocardial infarction. *Int J Cardiol*. 2017; 249:32-35.
- 18 Chew DP, Lambrakis K, Blyth A, et al. A randomized trial of a 1-hour troponin protocol in suspected acute coronary syndromes: The Rapid Assessment of Possible ACS in the Emergency Department with High Sensitivity Troponin T (RAPID-TnT) study. *Circulation* 2019;140(19):1543-1556.
- 19 Twerenbold R, Costabel JP, Nestelberger T, et al. Outcome of applying the ESC 0/1-hour algorithm in patients with suspected myocardial infarction. *J Am Coll Cardiol* 2019;74(4):483-494.
- 20 Stoyanov KM, Hund H, Biener M et al. RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. *Eur Heart J Acute Cardiovasc Care*. 2019;9(1):39-51.
- 21 Parsonage W, Greenslade J, Hammett C, et al. Validation of an accelerated high-sensitivity troponin T assay protocol in an Australian cohort with chest pain. *Med J Aust* 2014;200:161-165.
- 22 Reichlin T, Cullen L, Parsonage WA, et al. Two hour algorithm for triage towards rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac Troponin T. *Am J Med* 2015;128:369-79.
- 23 Meller B, Cullen L, Parsonage WA, et al. Accelerated diagnostic protocol using high-sensitivity cardiac troponin T in acute chest pain patients. *Int J Cardiol*. 2015;184:208-15.
- 24 McRae AD, Innes G, Graham M, et al. Comparative Evaluation of 2-Hour Rapid Diagnostic Algorithms for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin T. *Can J Cardiol*. 2017;33(8):1006-1012.
- 25 Wildi K, Cullen L, Twerenbold R, et al. Direct comparison of 2 rule-out strategies for acute myocardial infarction: 2-h accelerated diagnostic protocol vs 2-h algorithm. *Clin Chem*. 2017;63(7):1227-1236.
- 26 Than MP, Pickering JW, Dryden JM, et al. ICare-ACS (Improving Care processes for patients with suspected acute coronary syndrome): a study of cross-system implementation of a national clinical pathway. *Circulation* 2018;137(4):354-363.
- 27 Thygesen K, Alpert JS, Jaffe AS, et al. Fourth definition of myocardial infarction. *J Am Coll Cardiol* 2018;30:72(18):2231-2264.
- 28 Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med* 2002;346:2047-2052.
- 29 Lindahl B, Venge P, James S. The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. *Am Heart J* 2010;160:224-229.
- 30 Haaf P, Reichlin T, Twerenbold R, et al. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. *Eur Heart J* 2014;35(6):365-375.
- 31 Bjurman C, Larsson M, Johanson P, et al. Small changes in troponin T levels are common in patients with Non-ST-elevation myocardial infarction and are linked to higher mortality. *J Am Coll Cardiol* 2014;62(14):1231-1238.
- 32 Lindahl B, Venge P, Wallentin L. Troponin T Identifies Patients With Unstable Coronary Artery Disease Who Benefit From Long-Term Antithrombotic Protection. *J Am Coll Cardiol* 1997;29(1):43-48.
- 33 Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. *N Engl J Med* 1999;340(21):1623-1629.
- 34 Heeschen C, Hamm CW, Goldmann BU, et al. for PRISM study investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. *Lancet* 1999;354:1757-1762.
- 35 Lindahl B, Diderholm E, Lagerquist B, et al. Effects on mortality of long-term treatment with l.m.w. heparin in relation to troponin T level and ECG findings - a FRISC 2 substudy. *Eur Heart J* 2000;21(Suppl.):521.
- 36 Newby LK, Ohman EM, Christenson RH, et al. Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T-Positive Status: The PARAGON-B Troponin T Substudy. *Circulation* 2001;103:2891-2896.
- 37 Wallentin L, Lindholm D, Siegbahn A, et al. Biomarkers in relation to the effects of Ticagrelor compared with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a Substudy from the prospective randomized Platelet inhibition and Patient Outcomes (PLATO) Trial. *Circulation* 2014;129(3):293-303.
- 38 Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;130(25):e344-426.
- 39 Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. *Circulation* 2011;124(2):136-145.
- 40 Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from two large randomized clinical trials. *Circulation* 2012;125(2):280-288.
- 41 Nambi V, Liu X, Chambless LE, et al. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk: the Atherosclerosis Risk in Communities Study. *Clin Chem* 2013;59(12):1802-1810.
- 42 Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;128(16):e240-327.
- 43 Cramer G, Bakker J, Gommans F, et al. Relation of highly sensitive cardiac troponin T in hypertrophic cardiomyopathy to left ventricular mass and cardiovascular risk. *Am J Cardiol*. 2014;113(7):1240-1245.

- 44 McGill D, Talaulikar G, Potter JM, et al. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. *Clin Chim Acta* 2010;411(13-14):936-939.
- 45 K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *Am J Kidney Dis.* 2005;45 (4 Suppl 3):S1-153.
- 46 Artunc F, Mueller C, Bredhardt T, et al. Sensitive troponins- which suits better for hemodialysis patients? Associated factors and prediction for mortality. *PLoS One.* 2012;7(10):e47610.
- 47 Wolley M, Steward R, Curry E, et al. Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. *Clin Kidney J.* 2013;6(4):402-409.
- 48 Honneger Bloch S, Semple D, Sidhu K, et al. Prognostic value and long-term variation of high sensitivity troponin T in clinically stable haemodialysis patients. *N Z Med J.* 2014;127(1402):97-109.
- 49 Twerenbold R, Wildi K, Jeger C, et al. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. *Circulation* 2015;131(23):2041-2050.
- 50 Landeberg G, Jaffe AS, Gilon D, et al. Troponin elevation in severe sepsis and septic shock: the role of left ventricular dysfunction and right ventricular dilatation. *Crit Care Med* 2014;42(4):790-800.
- 51 Hillis GS, Welsh P, Chalmers J, et al. The relative and combined ability of high sensitivity cardiac troponin T and N-terminal pro-BNP to predict cardiovascular events and death in patients with type 2 diabetes mellitus. *Diabetes Care* 2014;37(1):295-303.
- 52 Everett BM, Brooks MM, Vlachos HE, et al. Troponin and cardiac events in stable ischemic heart disease and diabetes. *N Engl J Med.* 2015;373(7):610-620.
- 53 Latini R, Masson S, Anand IS, et al. Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients with Stable Chronic Heart Failure. *Circulation* 2007;116:1242-1249.
- 54 Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. *N Engl J Med* 2009;361:2538-2547.
- 55 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129-2200.
- 56 Latini R, Masson S, Pirelli S, et al. On the behalf of the GISSI-AF Investigators. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial fibrillation trial. *J Intern Med* 2011;269(2):160-171.
- 57 Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. *Lancet* 2016; 387:2302-2311.
- 58 Berg DD, Ruff C, Jarolim P, et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.038312>.
- 59 Lewandrowski K. Special topics: cardiac markers in myocarditis. Cardiac transplant rejection and conditions other than acute coronary syndrome. *Clin Lab Med* 2014;34:129-135.
- 60 Swaanenburg JC, Klaase JM, DeJongste M, et al. Troponin I, troponin T, CK-MB-activity and CK-MB mass as markers for the detection of myocardial contusion in patients who experienced blunt trauma. *Clin Chim Acta* 1998;272:171-181.
- 61 Bajaj A, Saleeb M, Rathor P, et al. Prognostic value of troponins in acute noninvasive pulmonary embolism. A meta-analysis. *Heart Lung* 2015;44(4):327-334.
- 62 Dubin RF, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). *BMC Nephrol* 2013;14(1):229.
- 63 Newby LK, Rodriguez I, Finkle J, et al. Troponin measurements during drug development-considerations for monitoring and management of potential cardiotoxicity. An educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. *Am Heart J* 2011;162(1):64-73.
- 64 Perrone MA, Spolaore F, Ammirabile M, et al. The assessment of high sensitivity cardiac troponin in patients with COVID-19: A multicenter study. *Int J Cardiol Heart Vasc.* 2021;32:100715.
- 65 Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coro-navirus Disease 2019 (COVID-19). *JAMA Cardiol.* 2020;5(7):811-818.
- 66 Wei JF, Huang FY, Xiong TY, et al. Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis. *Heart.* 2020;106(15):1154-1159.
- 67 De Michieli L, Ola O, Knott JD, et al. High-Sensitivity Cardiac Troponin T for the Detection of Myo-cardial Injury and Risk Stratification in COVID-19. *Clin Chem.* 2021.
- 68 Poterucha TJ, Elias P, Jain SS, et al. Admission Cardiac Diagnostic Testing with Electrocardiography and Troponin Measurement Prognosticates Increased 30-Day Mortality in COVID-19. *J Am Heart Assoc.* 2021;10(1):e018476.
- 69 Calvo-Fernandez A, Izquierdo A, Subirana I, et al. Markers of myocardial injury in the prediction of short-term COVID-19 prognosis. *Rev Esp Cardiol (Engl Ed).* 2020.
- 70 Willeit P, Welsh P, Evans JDW, et al., High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. *J Am Coll Cardiol* 2017;70(5):558-568.
- 71 deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. *JAMA* 2010;304(22):2494-502.
- 72 Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. *Circulation* 2011;123 (13):1367-1376.
- 73 Oluleye OW, Folsom AR, Nambi V, Lutsey PL, Ballantyne CM. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. *Ann Epidemiol* 2013;23 (2):66-73.
- 74 Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the Atherosclerosis Risk in Communities Study. *Stroke* 2013;44 (4):961-967.
- 75 Eggers KM, Al-Shakarchi J, Berglund L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. *Am Heart J* 2013;166(3):541-548.
- 76 Willeit P, Kaptoge S, Welsh P, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. *Lancet Diabetes Endocrinol* 2016;4(10):840-849.
- 77 Bosselmann H, Egstrup M, Rossing K, et al. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study *Int J Cardiol* 2013;170(2):202-207.
- 78 Wallentin L, Lindhagen L, Årnström E, et al. Early invasive versus noninvasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. *Lancet* 2016;388(10054):1903-1911.
- 79 Gillmann HJ, Meinders A, Grohennig A, et al. Perioperative levels and changes of high-sensitivity troponin T are associated with cardiovascular events in vascular surgery patients. *Crit Care Med* 2014; 42(6):1498-1506.
- 80 Botto F, Alonso-Coello P, Chan MT et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. *Anesthesiology* 2014; 120(3):564-78.

- 81 Puelacher C, Lurati Buse G, Seeberger D, et al. Perioperative myocardial injury after noncardiac surgery: incidence, mortality, and characterization. *Circulation*. 2018; 137(12):1221-1232.
- 82 Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). *Eur Heart J* 2014; 35(35):2383-431.
- 83 Duceppe E, Parlow J, MacDonald P, et al. Canadian cardiovascular society guidelines on perioperative cardiac risk assessment and management for patients undergoing noncardiac surgery. *Canadian Journal of Cardiology Can J Cardiol*. 2017;33(1):17-32.
- 84 Gualandro DM, Yu PC, Caramelli B, et al. 3rd Guideline for perioperative cardiovascular evaluation of the Brazilian society of cardiology. *Arq Bras Cardiol* 2017;109:1-104.
- 85 Davis GK, Labugger R, Van Eyk JE, et al. Cardiac troponin T is not detected in western blots of diseased renal tissue. *Clin Chem* 2001;47(4):782-783.
- 86 Ricchiuti V, Voss EM, Ney A, et al. Cardiac Troponin T isoforms expressed in renal diseased skeletal muscle will not cause false positive results by the second generation cTnT assay by Boehringer Mannheim; *Clin Chem* 1998;44(9):1919-1924.
- 87 Hallermayer K, Klennner D, Vogel R. Use of recombinant human cardiac troponin T for standardization of third generation troponin T methods. *Scand J Clin Invest* 1999;59(Suppl 230):128-131.
- 88 Wu AHB, Christenson RH, Greene DN et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. *Clin Chem* 2018; 64(4):645-655.
- 89 Giannitsis E, Mueller-Hennessen M, Zeller T et al. Gender-specific reference values for high-sensitivity cardiac troponin T and I in well-phenotyped healthy individuals and validity of high-sensitivity assay designation. *Clin Biochem* 2020; 78:18-24.
- 90 Saenger AK, Beyrau R, Braun S, et al. Multicenter analytical evaluation of a high-sensitivity troponin T assay. *Clin Chim Acta* 2011;412(9-10):748-754.
- 91 Rubini Giménez M, Twerenbold R, Boeddinghaus J, Nestelberger T et al. Clinical Effect of Sex-Specific Cutoff Values of High-Sensitivity Cardiac Troponin T in Suspected Myocardial Infarction. *JAMA Cardiol*. 2016;1(8):912-920.
- 92 Giannitsis E. Sex-specific troponin measures for diagnosis of acute coronary syndrome. *Heart* 2016; 102(2):91-92.
- 93 Mueller-Hennessen M, Lindahl B, Giannitsis E et al. Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T - Sub-analysis from the TRAPID-AMI study. *Int J Cardiol*. 2016;209:26-33.
- 94 Eggers KM, Jernberg T, Lindahl B. Prognostic importance of sex-specific cardiac troponin T 99(th) percentiles in suspected acute coronary syndrome. *Am J Med* 2016; 129 (8): 880.e1-880.e12.
- 95 Mueller-Hennessen M, Giannitsis E. Do we need to consider age and gender for accurate diagnosis of myocardial infarction?. *Diagnosis (Berl.)* 2016; 3(4):175-181.
- 96 Giannitsis E. Counterpoint: Potential Concerns Regarding the Use of Sex-Specific Cutpoints for High-Sensitivity Troponin Assays. *Clin Chem*. 2017; 63(1):264-266.
- 97 Twerenbold R, Boeddinghaus J, Nestelberger T, et al. Clinical use of high-sensitivity cardiac troponin in patients with suspected myocardial infarction. *J Am Coll Cardiol*. 2017;70(8):996-1012.
- 98 World Health Organization. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Nomenclature and criteria for diagnosis of ischemic heart disease. *Circulation* 1979;59:607-609.
- 99 Müller-Bardorff M, Hallermayer K, Schröder A, et al. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical validation. *Clin Chem* 1997;43(3):458-466.
- 100 Klein G, Kampmann M, Baum H, et al. Clinical performance of the new cardiac markers troponin T and CK-MB on the Elecsys 2010. A multicenter evaluation. *Wien Klin Wochenschr*. 1998;110(Suppl3):40-51.
- 101 Mendis S, Thygesen K, Kuulasmaa K, et al. World Health Organization definition of myocardial infarction: 2008-09 revision. *Int J Epidemiol* 2011;40(1):139-146.
- 102 Ferjani M, Droc G, Dreux S, et al. Circulating cardiac troponin T in myocardial contusion. *Chest* 1997;111(2):427-433.
- 103 Erbel C, Taskin R, Doesch A, et al. High-sensitive troponin T measurements early after heart transplantation predict short- and long-term survival. *Transpl Int* 2013;26(3):267-272.
- 104 Li SF, Zapata J, Tillem E. The prevalence of false-positive cardiac troponin I in ED patients with rhabdomyolysis. *Am J Emerg Med* 2005;23(7):860-863.
- 105 Zhang L, Wang GC, Ma L, et al. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review *Clin Cardiol* 2012;35(11):686-691.
- 106 Writing committee for the VISION study investigators, Devereaux JP, Biccard BM, Sigamani A, et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. *JAMA* 2017; 317(16):1642-1651.
- 107 Devereaux PJ, Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and management. *Eur Heart J* 2020;41(32):3083-3091.
- 108 Biccard BM, Rodseth RN. The pathophysiology of peri-operative myocardial infarction. *Anaesthesia* 2010;65(7):733-741.
- 109 DeFilippis AP, Young R, Carrubba CJ et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort *Ann Intern Med* 2015;162:266-275.
- 110 Andersson C, Enserro D, Larson MG et al. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. *J Am Heart Assoc* 2015;4(4):e001888.
- 111 Wolfson J, Vock DM, Bandyopadhyay S et al. Use and customization of risk scores for predicting cardiovascular events using electronic health record data. *J Am Heart Assoc* 2017;6(4):e003670.
- 112 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.
- 113 The Task Force for the diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST elevation acute coronary syndromes. *European Heart Journal* 2007;28:1598-1660.

For further information, please refer to the appropriate user guide or operator's manual for the analyzer concerned, the respective application sheets and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

The Summary of Safety & Performance Report can be found here: <https://ec.europa.eu/tools/eudamed>

## Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see [navifyportal.roche.com](http://navifyportal.roche.com) for definition of symbols used):

# Elecsys Troponin T hs



CONTENT	Contents of kit
SYSTEM	Analyzers/Instruments on which reagents can be used
REAGENT	Reagent
CALIBRATOR	Calibrator
→	Volume for reconstitution
GTIN	Global Trade Item Number

Rx only For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.



COBAS, NAVIFY, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2023, Roche Diagnostics



 Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
[www.roche.com](http://www.roche.com)  
 +800 5505 6606

